Want to join the conversation?
Drugmaker $MRK said that its expanded indication for KEYTRUDA (pembrolizumab) has been approved by the U.S. FDA as first-line therapy in patients with unresectable or metastatic melanoma, the second melanoma-related indication for the PD-1 inhibitor. The FDA-approved dose of KEYTRUDA is 2 mg/kg every three weeks.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.